Journal
ACS CHEMICAL NEUROSCIENCE
Volume 13, Issue 17, Pages 2540-2543Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.2c004612540
Keywords
psilocybin therapy; brain network modularity; S-citalopram; depression
Funding
- Steven and Alexandra Cohen Foundation
Ask authors/readers for more resources
This article raises several issues with a recent paper published in Nature Medicine, including inconsistencies in the reporting of clinical outcomes, statistical flaws, ambiguity and overinterpretation of resting state data, and the lack of a reference for a conceptually similar study. These issues cast doubt on the uniqueness and impact of the findings.
A recent paper in Nature Medicine found that psilocybin therapy in patients with depression decreased brain network modularity (measured with task-free functional magnetic resonance imaging), an effect supposedly not found with the selective serotonin reuptake inhibitor S-citalopram. This decrease in network modularity also correlated with depression. Here, we raise several issues with this paper, including inconsistencies in reports of the primary clinical outcome, statistical flaws including a one-tailed test, nonsignificant interaction, and regression to the mean, the ambiguity and overinterpretation of resting state data, and a missing reference for a conceptually similar study that exemplifies why a one-tailed test cannot be justified. Together, these issues make us question the uniqueness and impact of these findings, as well as the unwarranted media hype that they generated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available